Co-Diagnostics

Co-Diagnostics DSCR

The Debt Service Coverage Ratio (DSCR) of Co-Diagnostics (CODX) as of Nov 20, 2026 is -23.56. In the previous year, Debt Service Coverage Ratio (DSCR) was -13.55 — a change of 73.94% (lower).

DSCR

-23.56

YoY

73.94%

Last updated:

Debt Service Coverage Ratio (DSCR) of Co-Diagnostics is 2025 -23.56 . Debt Service Coverage Ratio (DSCR) of Co-Diagnostics was 2024 -13.55 . It decreases by 73.94% lower compared to the previous year.

The Co-Diagnostics DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2015
-1.51 USD
Jan 1, 2016
-0.39 USD
Jan 1, 2018
-2.14 USD
Jan 1, 2021
6.76 USD
Jan 1, 2022
18.88 USD
Jan 1, 2023
-7.38 USD
Jan 1, 2024
-13.55 USD
Jan 1, 2025
-23.56 USD
The Co-Diagnostics DSCR history
YEARDSCRYoY
-23.56+73.94%
-13.55+83.46%
-7.38-139.11%
18.88+179.09%
6.76-416.45%
-2.14+452.91%
-0.39-74.44%
-1.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Debt Service Coverage Ratio (DSCR) of Co-Diagnostics is -23.56 in 2025.

Debt Service Coverage Ratio (DSCR) of Co-Diagnostics changed from -13.55 to -23.56, representing a 73.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Co-Diagnostics

All Key Metrics — Co-Diagnostics